FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

header-info

On January 26, 2023, the Food and Drug Administration approved pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer.